BioSig Awarded CAGE Code by the Systems for Award Management (SAM)
August 03 2020 - 02:00PM
BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a
medical technology company commercializing a proprietary biomedical
signal processing platform designed to improve signal fidelity and
uncover the full range of ECG and intra-cardiac signals, today
announced that the Company has been awarded its Commercial and
Government Entity (CAGE) code by the Systems for Award Management
(SAM). The CAGE code is required to do business operations with the
federal government.
BioSig, along with its subsidiary ViralClear, are now registered
to conduct business with the U.S. government and can be sought out
by government agencies for contracts that fit the Company. The CAGE
code also includes the ability to apply and be awarded government
contracts, assistance and grant programs.
About SAMThe System for Award Management (SAM)
is a federal government owned and operated free website that
consolidates the capabilities in Central Contractor Registration
(CCR)/FedReg, Online Representations and Certifications
Applications (ORCA) and the Excluded Parties List System (EPLS).
Both current and potential government vendors are required to
register in SAM in order to be awarded contracts by the government.
SAM allows government agencies and contractors to search for
companies based on ability, size, location, experience, ownership,
and more. SAM allows users to search for firms certified by the SBA
under the 8(a) Development and Hubzone Programs. SAM validates the
vendor's information and electronically shares the secure and
encrypted data with the federal agencies' finance offices to
facilitate paperless payments through electronic funds transfer
(EFT). Additionally, SAM shares the data with government
procurement and electronic business systems.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About ViralClear Pharmaceuticals, Inc. and Merimepodib
(MMPD) BioSig’s Technologies, Inc (Nasdaq: BSGM)
subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), is
seeking to develop a novel pharmaceutical called merimepodib to
treat patients with COVID-19. Merimepodib is intended to be orally
administered, and has demonstrated broad-spectrum in vitro
antiviral activity, including strong activity against SARS-CoV-2 in
cell cultures. Merimepodib was previously in development as a
treatment for chronic hepatitis C and psoriasis by Vertex
Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7
in phase 1 and 5 in phase 2) with over 400 subjects and patients
and an extensive preclinical safety package was completed.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2023 to Mar 2024